Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells $205,072.97 in Stock

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) insider Pamela J. Cramer sold 4,099 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $50.03, for a total transaction of $205,072.97. Following the transaction, the insider now directly owns 13,500 shares in the company, valued at approximately $675,405. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Rhythm Pharmaceuticals Price Performance

RYTM traded up $0.22 during trading on Wednesday, hitting $49.31. 420,459 shares of the stock traded hands, compared to its average volume of 555,087. The firm has a 50-day moving average of $46.97 and a 200 day moving average of $42.73. Rhythm Pharmaceuticals, Inc. has a 12-month low of $20.97 and a 12-month high of $53.92. The firm has a market capitalization of $3.01 billion, a P/E ratio of -10.60 and a beta of 2.07.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last posted its earnings results on Tuesday, August 6th. The company reported ($0.55) earnings per share for the quarter, topping analysts' consensus estimates of ($0.71) by $0.16. Rhythm Pharmaceuticals had a negative net margin of 254.88% and a negative return on equity of 221.65%. The company had revenue of $29.08 million during the quarter, compared to analyst estimates of $28.79 million. During the same period in the prior year, the business posted ($0.82) earnings per share. Rhythm Pharmaceuticals's revenue for the quarter was up 51.3% on a year-over-year basis. As a group, equities analysts predict that Rhythm Pharmaceuticals, Inc. will post -4.44 EPS for the current fiscal year.

Institutional Investors Weigh In On Rhythm Pharmaceuticals

A number of large investors have recently made changes to their positions in the business. CWM LLC raised its holdings in shares of Rhythm Pharmaceuticals by 62.6% during the second quarter. CWM LLC now owns 657 shares of the company's stock valued at $27,000 after acquiring an additional 253 shares in the last quarter. American International Group Inc. increased its position in Rhythm Pharmaceuticals by 3.1% during the 1st quarter. American International Group Inc. now owns 26,318 shares of the company's stock valued at $1,140,000 after purchasing an additional 781 shares during the period. ORG Partners LLC bought a new position in Rhythm Pharmaceuticals in the 2nd quarter worth $51,000. Principal Financial Group Inc. lifted its position in shares of Rhythm Pharmaceuticals by 20.6% in the 1st quarter. Principal Financial Group Inc. now owns 7,180 shares of the company's stock worth $311,000 after purchasing an additional 1,227 shares during the period. Finally, Quest Partners LLC boosted its stake in shares of Rhythm Pharmaceuticals by 513.3% during the 2nd quarter. Quest Partners LLC now owns 1,662 shares of the company's stock valued at $68,000 after purchasing an additional 1,391 shares in the last quarter.

Analyst Ratings Changes

Separately, Needham & Company LLC reiterated a "buy" rating and issued a $55.00 price objective on shares of Rhythm Pharmaceuticals in a report on Wednesday, August 7th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $55.83.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.